To test this hypothesis we created two constitutively active Rasl11b molecules by introducing activating mutations based on the tumor-derived RAS mutations G12V and Q61L [58] (Materials and Methods, and Fig. 1A), thereafter both named Rasl11b* because of their similar influence. Here, RASL11B is linked to neoplasm.